The tripartite-harmonized International Conference on Harmonization reproductive guideline ( 1993) recommends administration of test substances for 4 weeks to male rats before mating. However, scientific or experimental rationale for this recommendation is not firmly based, and the most appropriate parameters have not been established in experimental models. Therefore, a team consisting of 16 Japanese pharmaceutical companies and the National Institute of Health Sciences performed a collaborative study to determine the optimal period and parameters for detection of male fertility disorders in rats. Sixteen compounds, including four anticancer drugs, two psychotropic drugs, two nootropic drugs, two vitamins, two hormones, one antihypertensive agent, one diuretic drug, and two general chemicals were administered to male rats for 4 or 9 weeks before mating. Parameters used to examine effects on the male reproductive system were organ weights, spermatogenic endpoints, mating behavior, cesarean section findings, and histopathology. From the results, treatment for 4 weeks before mating was concluded to be sufficient to detect adverse effects on male fertility, with the histopathology of the testis being the most sensitive index for the drugs used. Sperm parameters, especially number, and genital organ weight determination provided information confirming toxicity. Tests of reproductive activity were generally found to be insensitive, except where the drugs affected sperm maturation. Based on this study, it is concluded that a 4-week treatment period is appropriate for detection of drug effects on male fertility, and that histopathological examination of the testis is the most sensitive approach.
and accessory male genital organs were weighed. Ten companies measured paired weights of the testes and six companies weighed them separately. The epididymides were taken as paired weight by 11 companies, and separately by the remainder. All companies determined the weights of the prostate gland and seminal vesicles individually. The numbers, morphology, and/or activity of sperm were examined. The testes, epididymides, and accessory male genital glands were fixed in Bouin's solution, routinely processed for sectioning and staining with H&E or periodic acid-Schiff s solution (PAS), and examined histopathologically. In female rats the numbers of corpora lutea, implantations, resorptions, and dead and live fetuses were counted. Fetuses were weighed, and inspected for external anomalies. Optional examinations included a recovery test, hormone assays, segment I1 or I11 studies, repeated dose toxicity studies, and investigation of pharmacokinetics. Ten companies used the same statistical analyses, viz, data such as those for weights or numbers were first tested by Bartlett's test for homogeneity of variance. If the variance was homogeneous, a one-way analysis of variance was applied. When the results indicated a significant difference among the groups, the Dunnett's or Scheffe's test was performed to compare each dosed group with the control group. If the variances were heterogeneous, the Kruskal-Wallis rank analysis was applied. When the results indicated a significant difference among the groups, the mean ranks of the dosed groups were compared with that of the control, using a Dunnett's or Scheffe's test. The remaining companies used the Student's f test or Aspin-Welch t test followed by the F test, or Duncan's multiple comparison or Tukey's test followed by one-way analysis of variance. Categorical data such as indices or rates were mainly analyzed by the x2 test or Fisher's exact method.
The investigations of 13 companies followed the guidelines of their own companies for the care and use of laboratory animals, and the remaining 3 companies complied with the guidelines for animal experimentation issued by the Japanese Association for Laboratory Sciences (1987) .
The study design is illustrated in Fig. 1 .
RESULTS OF INDIVIDUAL STUDIES
The summary results for the individual chemicals are presented in Table 2 .
Male Sprague-Dawley rats were orally given daily doses of 5 , 10, 20, or 40 mglkg body weight for 2 weeks, and 2.5, 5, or 10 mg/kg body weight for 4 and 9 weeks. The testis and epididymis weights were not affected by the treatment. The numbers of spermatogonia in the seminiferous tubules were decreased in the 20 and 40 mg/kg body weight groups after 2 weeks of treatment and remained unchanged after 4-and 9-week treatments. Numbers of testicular sperm were not affected. All male rats were found dead or killed in the 40 mg/kg body weight group during 2-week treatment, or in the 10 mg/kg body weight group during 9-week treatment. The implantation rate was decreased in the 20 mg/kg body weight group after 2-week treatment, and in lower dose levels after 4-and 9-week treatments. Postimplantation losses were increased in all dosage groups after 2-, 4-, and 9-week treatments.
Estradiol Benzoate
The compound was given subcutaneously to Sprague-Dawley male rats at dose levels of 0.005,0.05, or 0.25 mg/kg for 2 weeks as a preliminary study, and 0.0002, 0.002, or 0.02 mg/kg for 4 and 9 weeks. After the 2-week dosing period, the testis, epididymis, prostate gland, and seminal vesicle weights were reduced in the 0.05 and 0.25 mg/kg groups, as was prostate weight in the 0.005 mg/kg group. Similar changes were also found in the 0.02 mg/kg group after 4-and 9-week treatments. The prostate gland and seminal vesicle weights were reduced in both 0.002 and 0.02 mg/kg groups. After 2-week dosing, atrophy of the testis and epididymis, exfoliation and degeneration of germ cells in the testis, and absence of spermatozoa in the testis and epididymis were evident in the 0.25 mg/kg group. After 4-and 9-week dosing, atrophy of Leydig cells and mature spermatid retention at Stage IX, X, and XI were observed in the 0.002 and 0.02 mg/kg groups. After 2-week dosing, the number and motility of sperm decreased in the 0.05 and 0.25 mg/kg groups. After 4-week treatment, the number and motility of sperm in the epididymides were not affected by treatment. After 9-week dosing, the epididymal sperm number, as well as motility, were decreased in the 0.02 mg/kg groups. After 2-week treatment, although copulation was confirmed in the 0.05 mg/kg group, no male rats impregnated female rats. No male rats copulated in the 0.25 mglkg group. In the 0.005 mg/kg group, postimplantation failure was M, +31.8%
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Pyri- Nitrazepam was orally administered to Sprague-Dawley male rats at daily doses of 20, 40, or 80 mg/kg body weight for 2, 4, and 9 weeks. Decreased testis and epididymis weights were consistently observed in the 40 and 80 mg/kg groups. Testicular toxicity was characterized histopathologically by hypospermatogenesis, decreased diameters of seminiferous tubules, and Leydig cell hyperplasia in the 80 mg/kg group after 2-week treatment, and these changes were also noted in the lower dose levels after 4-and 9-week treatments. Necrosis of pachytene spermatocytes was observed in the 20 mg/kg group after 4-week treatment. More extensive damage involving both spermatocytes and spermatids was present in the 40 and 80 mg/kg groups after 2, 4, and 9 weeks. The numbers of testicular sperm were decreased, but the sperm were motile in the 40 and 80 mg/kg groups after 2-, 4-, and 9-week treatments. Although the copulation index was not affected, the successful pregnancy rate was very low in the 80 mg/kg group after all treatment periods, and preimplantation failure was increased in the 80 mg/kg group after 2-and 4-week treatments.
Adriamycin
The compound was intravenously administered to Sprague-Dawley male rats once a week at doses of 1 or 2 mg/kg body weight for 4 and 9 weeks. The weights of the testes and/or epididymides in the 1 and 2 mg/kg groups of the 4-and 9-week treatment were significantly reduced. Weights of prostate glands and seminal vesicles were decreased in the 2 mglkg group after 4-week or 9-week treatment, respectively. The numbers of spermatogonia and/or spermatocytes decreased after 4-week treatment in the 1 and 2 mg/kg groups but normal spermatozoa were observed in most of the seminiferous tubules. After 9-week treatment, testicular lesions in the 1 and 2 mg/kg groups became evident; in the 2 mg/kg group, all spermatogenic epithelium was lost in the tubules, which were markedly atrophied, showing only Sertoli cells. Spermatogonia and spermatocytes were absent in all tubules in the 1 mg/kg group after 9-week treatment, but normal spermatids and spermatozoa were still present. Although the epididymides, prostate glands, and seminal vesicles revealed no structural changes after the 4-week treatment period, atrophy was present after 9 weeks. Sperm counts and viability were extremely low in the 1 and 2 mg/kg groups after 9-week treatment. No fertility was evident for the 2 mg/kg group and the implantation rate and number of live fetuses were significantly decreased in the 1 mg/kg group after 9-week treatment.
Compound C
The drug was intravenously administered at doses of 1, 3, or 10 mg/kg body weight for 4 weeks, and 0.3, 1, or 3 mg/kg body weight for 9 weeks. Epididymis, prostate glands, and seminal vesicle weights in the 10 mgkg group were significantly lower, and the testis weight in the 10 mg/kg group was higher after 4-week treatment than those of the controls. Extended seminiferous tubules with vacuolated spermatocytes were evident in the 10 mg/kg group after 4-week treatment.
No histopathological changes were noted in the testis even in the high-dose (3 mg/kg) group after 9-week treatment. The number of sperm in the testis was decreased in the 10 mg/kg group after 4-week treatment. Copulation and fertility indices in the treated groups were comparable to those of the control groups. The implantation rate, as well as the number of live embryos, were decreased in the 10 mg/kg group after 4-week treatment.
Compound E Compound E was administered orally to Sprague-Dawley male rats at doses of 12.5, 25, or 50 mg/kg body weight for 4 and 9 weeks. The testis weight was decreased in the 50 mg/kg group of 4-and 9-week treatment, and the epididymis weight of the 25 and 50 mg/kg groups was lower than that of the control group after 9-week treatment. Atrophy of seminiferous tubules and reduced numbers of sperm cells, as well as desquamated seminiferous epithelia in the epididymus, were evident in the 50 mg/kg group after 4-week treatment. After 9-week treatment, atrophy of seminiferous tubules and desquamated seminiferous epithelia were observed in the 25 and 50 mg/kg groups in a dose-related manner. In the 50 mg/kg group, seminiferous tubules were severely depleted with germ cells and accompanied with Leydig cell hyperplasia. Desquamation and single cell necrosis of seminiferous epithelium were noted in the 50 mg/kg group. The numbers of sperm were decreased in the 50 mg/kg group after 4-and 9-week treatments. Although the pregnancy outcome was not affected by 4-week treatment, no animals became pregnant in the 50 mg/kg group after 9-week treatment. These testicular changes in terms of numbers of testicular sperm and severity of histopathological lesions were reversible after an 8-week recovery period in the 4-week treatment group.
Compound T
The compound was administered orally to male Wistar rats at dose levels of 10 or 50 mg/kg body weight for 4 weeks, and 2, 10, or 50 mg/kg for 9 weeks. Prostate gland weight in the 50 mg/kg group was significantly lower than that in the control group after 4-week treatment. Desquamation of round spermatids in the testis was observed in the 50 mg/kg group after 4-week treatment. Spermatid/spermatocyte degeneration was present in the testes and epididymides in the 50 mg/kg group after 9-week treatment. No adverse effects were detected in terms of epididymal sperm activity, motility, or number. The copulation and fertility indices in the treated groups were comparable to those of the control group. After 9-week treatment, increased preimplantation loss and fewer implants and live fetuses were noted in the 50 mg/kg group in comparison with control group values. After a recovery period of 6 weeks, mating of 13-week treated males rats with nontreated female rats resulted in copulation and fertility indices, pre-and postimplantation losses, and numbers of implants and live fetuses comparable to those in the control group. Dosing with 50 mg/kg for 13 weeks lowered the serum testosterone level.
Haloperidol
Haloperidol was orally administered to Sprague-Dawley male rats at daily doses of 3, 10,30, or 60 mg/kg body weight for 4 weeks, and 3, 10, or 30 mg/kg for 9 weeks. The testis weight was decreased in the 60 mg/kg group after 4-week treatment, and in the 10 and 30 mg/kg groups after 9-week treatment. After 4 weeks of dosing with 60 mg/kg, mild necrosis of pachytene spermatocytes of stage VII in seminiferous tubules, exfoliation of round spermatids into the lumen, atrophy of Leydig cells, cell debris in the lumen of the epididymis, and atrophy of epithelial cells in the seminal vesicle were noted. The numbers of pachytene spermatocytes in stage VII and XI1 seminiferous tubules were also decreased. In addition, slight atrophy of Leydig cells was observed in the 30 mg/kg group after 4-week dosing. Although the copulation index was not affected, the fertility index in the 60 mg/kg group after 4-week treatment was significantly lower than that of the control group.
Nefiracetam
Sprague-Dawley male rats were administered nefiracetam orally at daily doses of 500 or 1,500 mg/kg for 4 and 9 weeks. Testicular weight was decreased in the 1,500 mg/kg group after both treatment periods. Epididymis and prostate gland weights were also reduced in the 500 mg/kg group after 9-week treatment and in the 1,500 mg/kg group after 4 and 9 weeks. Severe degeneration was observed in the seminiferous tubules in the 1,500 mg/kg group at both 4 and 9 weeks. Retention of sperm in stage IX, X, and XI seminiferous tubules was also noted in the 500 mg/kg group after 4-and 9-week treatments. The numbers of testicular sperm were markedly decreased in the 1,500 mg/kg group at the end of both treatment periods, and mildly reduced in the 500 mg/kg group after 4-week treatment. Although the copulation index was not affected by nefiracetam treatment, fertility indices were extremely low in the 1,500 mg/kg group after both treatment periods.
Nitrofurazone
The compound was orally administered to Sprague-Dawley male rats at daily doses of 12.5, 25, or 50 mg/kg body weight for 4 weeks, and 12.5 or 25 mg/kg for 9 weeks. The 9-week examination has not yet been completed. Testicular and epididymal weights decreased, and degeneration of seminiferous tubules, as well as hyperplasia of Leydig cells, were noted in the 25 and 50 mg/kg groups after 4-week treatment. Numbers of sperm in the testis were decreased in the 25 and 50 mg/kg groups after 4-week dosing. The copulation index and fertility index were decreased, and pregnancy was absent in the 50 mg/kg group. A decreased fertility index and increased pre-and postimplantation failure were observed in the 25 mg/kg group.
Reserpine
Reserpine was subcutaneously administered to Sprague-Dawley male rats at daily doses of 0.05,O. 1, or 0.2 mg/kg body weight for 4 and 9 weeks. The prostate gland weights were decreased in the 0.05, 0.1, and 0.2 mg/kg groups after 4-week treatment. Likewise, the testis and prostate gland weights were decreased in the 0.1 and 0.2 mg/kg groups after 9-week treatment. After 4 weeks, spermatid retention at step 19 was noted in seminiferous tubules of stages IX-XII, and necrosis of germinal epithelia was noted in all of the treated groups. The number, motility, and abnormality of sperm were not affected by the compound. Although copulation and fertility indices were not affected by the compound, the numbers of implantations and live fetuses were decreased by 4-week treatment with 0.05 and 0.2 mg/kg. The number of implantations was decreased by the 9-week treatment with 0.1 mg/kg.
Spironolactone
The compound was administered orally to Sprague-Dawley male rats at daily doses of 100 or 200 rng/kg body weight for 4 weeks, and 50 or 100 mg/kg for 9 weeks. The 9-week examination has not yet been completed. Epididymal and seminal vesicle weights were decreased by the 4-week treatment with 100 or 200 mg/kg, and prostate gland weights were decreased in the 200 mg/kg group. The seminal vesicles became atrophic in the 100 and 200 mg/kg groups, and the prostate gland atrophied in the 200 mg/kg group. The treatment did not affect spermhead count. Postimplantation failure was increased in the 100 and 200 mg/kg groups, although copulation and fertility indices were not affected.
a-Chlorohydrine
Sprague-Dawley male rats received the compound orally at daily doses of 2 or 8 mg/kg body weight for 2 weeks. The testis, prostate glands and epididymis weights in the treated groups were comparable to those of the controls. Significant histopathological changes were absent in the testis and epididymus. Sperm motility in the 8 mg/kg group and sperm activity in the 2 and 8 mg/kg groups were decreased, but the number, viability, and maturation of sperm remained unchanged. Although the copulation rate of the treated group was the same as that of the control group, there were no pregnant females in the 8 mg/kg group. Two weeks after compound withdrawal, sperm motility and activity returned to normal, and pregnancy resulted from mating.
Ethinyl Estradiol
The compound was administered orally at doses of 0.1,0.3, 3, or 10 mglkg for 4 weeks. The testis, epididymis, prostate glands, and seminal vesicle weights in the treated groups were lower than in the control group, in a dose-related manner. Degeneration and exfoliation of spermatocytes and spermatids in the testis were observed in one male rat from each of the 0.1 and 0.3 mg/kg groups, and from all male rats of the 3 and 10 mg/kg groups. Additionally, vacuolation of Sertoli cells and atrophy of Leydig cells in the testis were found in all treated groups in a dose-related manner. Sperm number in the epididymis decreased in all treated groups, and sperm could hardly be found in the 3 and 10 mg/kg groups. The motility of sperm in the epididymis was not affected by treatment with the compound in the 0.1 and 0.3 mg/kg groups. Reproductive ability disappeared in the 3 and 10 mg/kg groups.
Etretinate
Sprague-Dawley male rats were given daily doses of 5 or 25 mg/kg body weight orally for 4 weeks. The testis, epididymis, seminal vesicle, and prostate gland weights in the 25 mg/kg group were lower than those in the control group. After 4-week dosing at the 25 mg/kg level, histopathological examination of the testis showed atrophy of seminiferous tubules and Leydig cells, necrosis of spermatids and spermatocytes, vacuolation of nuclei of spermatids and spermatocytes, and giant-cell formation in the seminiferous tubules. In the epididymides, decreased sperm number, degenerative spermatogenic cells in the ducts, and degeneration of epithelium were observed. In addition, atrophy of epithelium and coagulation glands in the seminal vesicle, as well as atrophy and degeneration of the epithelium in the prostate gland were observed. The male rats receiving 25 mg/kg had a decrease in numbers of sperm in the testis and caudal epididymis. None of the male rats mated with untreated female rats in the 25 mg/kg group.
Nitrazepam
Nitrazepam was given to Sprague-Dawley male rats orally at daily doses of 20, 40, or 80 mg/kg body weights for 4 weeks. The testis weights in the 40 and 80 mg/kg groups and the epididymis weight in the 80 mg/kg group were lower than in the control group. As testicular signs of toxicity, hypospermatogenesis and vacuolization of Sertoli cells in the seminiferous tubules were noted in the 40 and 80 mg/kg groups. In the epididymal ducts, cell debris was observed in the 40 and 80 mg/kg groups and the numbers of sperm were decreased in the 80 mg/kg group. Leydig cells were hyperplastic and hypertrophic in the 80 mg/kg group. Testicular head counts were decreased and the numbers of epididymal sperm abnormalities increased in the 40 and 80 mg/kg groups. Sperm motility was decreased in the 80 mg/kg group. In the findings from reproductive performance testing, significant decrease in the fertility index was observed in the 80 mg/kg group, although the mating index did not differ significantly from that of the control group. The treatment did not affect the concentration of testosterone in the plasma and the testis.
Pyridoxine
Pyridoxine was injected intraperitoneally into Sprague-Dawley male rats at daily doses of 250 or 500 mg/kg for 2 , 4 , and 6 weeks. After 4-week treatment, the testis, epididymis, and seminal vesicle weights in the 500 mg/kg group were lower than in the control group. The epididymal weight was decreased in the 500 mg/kg group after 6-week treatment. Slight vacuole formation in the seminiferous tubules was observed in the 250 and 500 mg/kg groups after 2-week treatment. In addition, reduction of spermatid numbers, and degeneration and loss of germ cells were seen after 4-week treatment with 500 mg/kg. At 6 weeks, these changes had become advanced and were accompanied by edema and atrophy of seminiferous tubules. In the epididymis, reduced numbers of sperm and clumps of desquamated cells became evident in the 500 mg/kg group after 4-and 6-week treatments. No changes were noted in the seminal vesicle or prostate gland. The motility and velocity of sperm were decreased in the 250 and 500 mg/kg group after 4-and 6week treatments. Although the copulation indices in the treated groups were comparable to that of the control group, none of the female rats mated with 4-and 6-week treated male rats of the 500 mg/kg group became pregnant.
DISCUSSION
The duration of drug treatment, as well as the selection of doses and endpoints to be tested, play important roles in determining whether sterility will occur. Several reports (Chapin, 1988; Zenick and Clegg, 1989; Takayama, 1992; Takayama and Hayashi, 1993) have indicated that histopathological examination of the testis allows shortening of the duration of compound administration from the traditional 9 weeks used for reproductive toxicity studies. Because there have hitherto been no comprehensive, well-designed experiments to compare toxicities and effects on male fertility between 4-and 9-week treatments, one of the most important objectives of this collaborative work was to cast light on this problem. The practical reason why durations of 4 and 9 weeks were selected was to ascertain whether male fertility disorders observed after 9-week treatment can be reliably detected in short-term repeated toxicity studies of only 4-week duration.
Twelve compounds were administered for both 4 and 9 weeks before mating. Haloperidol proved more toxic after 4-week treatment than after 9-week administration, in terms of histopathological changes in the testis. Although almost all compounds show dose-and time-dependent toxicities in general, several compounds such as haloperidol, which affect the endocrine system involving feedback mechanisms, are known to exhibit fluctuation of toxic effects with repeated dosing (Baker and Tucker, 1968) . No significant differences in any of the endpoints tested were found between 4-and 9-week treatment with compounds C. The remaining compounds, such as adriamycin, compound E and T, cyclophosphamide, estradiol benzoate, nefiracetam, nitrazepam, and reserpine showed toxicity after 4 weeks of treatment, but the toxic changes were more marked after 9 weeks. Therefore, all of the 10 compounds tested demonstrated induction of male fertility disorders within 4 weeks of treatment before mating.
Another major objective of this collaborative study was to establish appropriate test parameters. The reliability of the following was examined: histopathology of testis, sperm examination, genital organ weights, and fertility. Histopathological observation generally includes the epididymis and accessory glands as well as the testis. Genital organs weighed include the testes, epididymis, seminal vesicles, and prostate gland. Fertility generally encompasses mating ability, fertility, and pregnancy outcomes.
The summary results of each compound that induced male fertility disorders are listed in Table 2 . When findings from histopathology of testis, sperm examination, weights of genital organs, and fertility are compared, the doses of 13 of 16 compounds inducing histopathological changes in the testis were lower than those causing significant changes in other test parameters. These 13 compounds include adriamycin, compounds C, E, and T, estradiol benzoate, ethinyl estradiol, etretinate, nefiracetam, nitrazepam, nitrofurazone, pyridoxine, reserpine, and spironolactone. The two remaining compounds, cyclophosphamide and haloperidol, also had histopathological changes in the testis, but the lowest toxic doses were revealed by fertility in the cyclophosphamide case, and by genital organ weights with haloperidol. Because cyclophosphamide is so toxic that even a single administration can cause testicular disorders, the best endpoint will depend on dose and duration. Histopathological changes in the testis together with decreased genital weights were observed after 4-week haloperidol treatment. However, no pathological changes were evident after 9-week administration. Haloperidol may cause decrease of genital organ weights by depression of gonadotropic hormone secretion (Dickerman et al., 1974; Krieg and Johnson, 1981) , and exhibit fluctuation of toxic effects with repeated dosing (Baker and Tucker, 1968) . The category of drugs used tends to characterize the histopathological findings in the testis. Decrease/loss of spermatogonia was noted with drugs targeting these cells such as anticancer drugs, and necrosis/loss of spermatocytes and spermatids appeared with drugs affecting hormones via the neuroendocrine system of the hypothalamus, such as nootropic drugs and estrogens. Psychotropic drugs, which suppress the secretion of gonadotropic hormones and stimulate prolactin secretion, caused slight degenerative changes of spermatids, and stage analysis revealed high frequency of retention of spermatids (step 19) in seminiferous tubules at stages IX-XI. On the other hand, a-chlorohydrine, which affects sperm maturation in the epididymis, caused disorders evident on sperm examination and in terms of fertility. Nevertheless, histopathological changes were present in both the testis and the epididymis of male rats after 5-day treatment with 100 mg/kg of this compound (Kalla and Chohan, 1980; Jones, 1978) .
Male sterility, other than the testicular damage detected on histopathological observation, includes abnormalities of sperm transport, maturation, and storage in the duct system, as well as changed secretory products from accessory glands, mating behavior, and pregnancy outcome. Sperm counts may be determined using ejaculated sperm, or sperm from vas deferens, epididymal, or testicular samples. In this study, five companies collected sperm from the testis; eight from the epididymis; and the remaining three from both the testis and the epididymis. Sperm examinations included sperm-head counts, numbers of sperm, abnormalities, motility, and viability. Sperm-head count or number of sperm were sensitive indicators for seven compounds: two anticancer drugs (adriamycin, compound E); two hormones (estradiol benzoate, ethinyl estradiol); one nootropic agent (nefiracetam); one vitamin (etretinate); and one psychotropic drug (nitrazepam). Sperm-head counts of homogenization-resistant spermatids (Amann, 198 1 ; Meistrich, 1989 ) were simpler and more reproducible than determining numbers of sperm in the caudal epididymis in our studies. a-Chlorohydrine exerted more toxicity in terms of sperm activity than other parameters such as number, motility, maturation, viability, or abnormalities. This compound also affected sperm maturation in the epididymis. Animals treated with compound C, nitrazepam, nitrofurazone, and pyridoxine exhibited decreased sperm-head counts, but other tests were not performed. Compound T, cyclophosphamide, haloperidol, reserpine, and spironolactone did not produce any changes in sperm count, activity, motility, morphology, or abnormalities, although histopathological changes were noted in the testis. Sperm evaluation techniques have already been established for domestic animals. However, routine techniques for rats have yet to be developed, especially for measurement of motility and viability. Therefore, sperm count either in the testis or epididymis, together with observation of their motility, are concluded to be the most appropriate parameters for sperm examination.
Fertility parameters generally include copulation index, number of corpora lutea, implants, fertility index, number of live and dead fetuses, and abnormalities of fetuses. Much evidence suggests that fertility is less sensitive than numbers of sperm for detecting male fertility disorders (Amann, 1981 (Amann, , 1982 Robaire et al., 1984; Meistrich, 1982 Meistrich, , 1989 Zenick and Goeden, 1988) . In the present collaborative work, higher doses were necessary to induce fertility changes in comparison to other examinations and, therefore, the sensitivity of this approach is limited.
It appears that reduction in one or more male reproductive organ weights is a sensitive endpoint. However, it is not possible to identify whether these observations were selective effects on the male reproductive organs or effects that were associated with generalized toxicity. Toxicokinetics and endocrinological examinations are thus particularly important in clarifying the details of toxicity in this regard and to clarify putative mechanisms of disorders. In the present study, toxicokinetics were not routinely examined, but compound T, which possesses a long serum half-life, had more pronounced toxicity after 9-week treatment than after only 4 weeks. Decreased testosterone levels were observed after treatment with compound T, etretinate, and nefiracetam. Thus, toxicokinetic and endocrinological parameters may not always be applicable in the detection of male infertility; they may contribute to mechanistic approaches.
The copulation index is a very practical parameter for assessing mating behavior and libido in rats. Spironolactone (Dukes, 1988) , estrogens (Eickstedt and Lang, 1989) , and reserpine (Bayne et al., 1980) produce loss of libido in humans. However, these drugs did not decrease the copulation rate in the present studies. Sexual behavior is complicated, involving central and peripheral nervous system neural and endocrinological activities, and it is particularly difficult to identify loss of libido using rats (Zenick and Goeden, 1988) .
The pregnant females were killed on day 20 of gestation, just before parturition, and fetuses were examined for external abnormalities. Teratogenicity has been observed in fetuses born from dams receiving adriamycin (Thompson et al., 1978) , cyclophosphamide (Chaube et al., 1967; Fritz and Hess, 1971) , and nitrofurazone (Greenaway et al., 1986; Nomura et al., 1975) , and mammalian germ-cell mutagenicity has also been described for adriamycin (Risley et al., 1988; Meistrich et al., 1990 ) and cyclophosphamide (Risley et al., 1988) . Although male-mediated teratogenesis was investigated in fetuses born from fathers receiving adriamycin for 4 and 9 weeks before mating, no significant increase of teratogenicity was detected.
Five recovery studies of male fertility disorders were conducted in the present series. Reproductive functions, as assessed by numbers of sperm, copulation, and fertility, recovered within 2 4 weeks after the withdrawal of a-chlorohydrine, compounds E and T, ethinyl estradiol, and nitrazepam. On the other hand, longer duration was required for morphological changes in the testis to be repaired. Microscopic observation revealed decreases in lesions within 4 weeks after 4-week treatment with compound E and ethinyl estradiol. However, they were still present 9 weeks after withdrawal of nitrazepam administration. Therefore, it is clear that morphological recovery of the testis takes a longer period than functional recovery does.
Although the data presented in this report are limited and variable, the present comprehensive collaborative work revealed that the presence of histopathological changes in the testis is the most reliable parameter for detecting male infertility induced by drugs. Furthermore, the present data suggest that the male premating treatment period can be shortened from 9 to 4 weeks without any loss in assay predictiveness.
Original manuscripts of the 16 studies are to be published as a special issue of the Journal of Toxicological Sciences in the fall of 1995.
